386. Long-term Complications Associated with COVID-19 Infection

Abstract Background In Michigan, 44,964 (68%) of the 66,269 COVID-19 patients have recovered. However, there is concern that COVID-19 infection may lead to long-term sequelae, including pulmonary defects, cardiac complications, blood clots, and neurocognitive impairment. This study describes the 30-day outcomes of patients who had recovered. Methods From 3/16/2020 to 5/19/2020, a follow-up was attempted for patients who were discharged alive from Henry Ford Hospital in Detroit and had recovered. Recovery was defined as being alive 30 days post symptom-onset. A telephone survey was conducted 30 days post-index admission and recorded in electronic medical records. Oxygen (O2) requirements, symptoms, readmissions and the need for antibiotics for secondary bacterial infections were evaluated. Results 585 patients met inclusion criteria and were contacted by phone; 303 answered their phone (Table 1), but only 266 (45%) completed a full telephone encounter and were included in the final analysis (Table 2). The majority were female (53%), black (80%), and discharged to home (84%). The clinical characteristics of those who completed the survey were as follows: 11% presented with O2 saturation < 90%, 16% had underlying lung pathology, and 57% had a BMI above 30. Patients’ average age was 61 ± 14.3 years. At 30 days post-index admission, 49% were still symptomatic. Of the symptomatic patients, 86% had dyspnea on exertion and 15% required O2 supplementation. 18% of patients were readmitted within 30 days, and 9% developed a secondary infection prior to the phone encounter. No statistically significant differences in demographics or comorbidities were found between symptomatic and asymptomatic cohorts (Tables 1, 2). Conclusion In our study, almost half of the discharged patients remained symptomatic after 30 days with a substantial proportion experiencing pulmonary symptoms. A better understanding of the long-term pulmonary sequelae following COVID-19 infection is needed to design interventions to reduce post-infectious morbidity. Disclosures Indira Brar, MD, Gilead (Speaker’s Bureau)janssen (Speaker’s Bureau)ViiV (Speaker’s Bureau)

Download Full-text

Might Routine Vitamin A Monitoring in Cystic Fibrosis Patients Reduce Virus-Mediated Lung Pathology?

Frontiers in Immunology ◽

10.3389/fimmu.2021.704391 ◽

2021 ◽

Vol 12 ◽

Author(s):

Robert E. Sealy ◽

Sherri L. Surman ◽

Peter Vogel ◽

Julia L. Hurwitz

Keyword(s):

Cystic Fibrosis ◽

Vitamin A ◽

Bacterial Infections ◽

Viral Infections ◽

Recessive Gene ◽

Lung Pathology ◽

Cell Integrity ◽

Routine Monitoring ◽

Immune Health

Cystic fibrosis (CF) is an autosomal recessive gene disorder that affects tens of thousands of patients worldwide. Individuals with CF often succumb to progressive lung disease and respiratory failure following recurrent infections with bacteria. Viral infections can also damage the lungs and heighten the CF patient’s susceptibility to bacterial infections and long-term sequelae. Vitamin A is a key nutrient important for immune health and epithelial cell integrity, but there is currently no consensus as to whether vitamin A should be monitored in CF patients. Here we evaluate previous literature and present results from a CF mouse model, showing that oral vitamin A supplements significantly reduce lung lesions that would otherwise persist for 5-6 weeks post-virus exposure. Based on these results, we encourage continued research and suggest that programs for the routine monitoring and regulation of vitamin A levels may help reduce virus-induced lung pathology in CF patients.

Download Full-text

Minimum 10-Year Clinical Outcome of Lateral Collagen Meniscal Implants for the Replacement of Partial Lateral Meniscal Defects: Further Results From a Prospective Multicenter Study

Orthopaedic Journal of Sports Medicine ◽

10.1177/2325967121994919 ◽

2021 ◽

Vol 9 (5) ◽

pp. 232596712199491

Author(s):

Alberto Grassi ◽

Gian Andrea Lucidi ◽

Giuseppe Filardo ◽

Piero Agostinone ◽

Luca Macchiarola ◽

...

Keyword(s):

Survival Rate ◽

Case Series ◽

Final Analysis ◽

Activity Level ◽

Long Term Results ◽

Level Of Evidence ◽

Unicompartmental Knee Arthroplasties ◽

Tegner Score

Background: The collagen meniscal implant (CMI) is a biologic scaffold aimed at replacing partial meniscal defects. The long-term results of lateral meniscal replacement have never been investigated. Purpose: To document the clinical outcomes and failures of lateral CMI implantation for partial lateral meniscal defect at a minimum 10-year follow-up. Study Design: Case series; Level of evidence, 4, Methods: This study included 24 consecutive patients who underwent lateral CMI implantation for partial lateral meniscal defects between April 2006 and September 2009 and who were part of a previous study with a 2-year follow-up. Outcome measures at the latest follow-up included the Lysholm score, Knee injury and Osteoarthritis Outcome Score, visual analog scale (VAS) for pain, Tegner activity level, and EuroQol 5-Dimensions score. Data regarding complications and failures were collected, and patients were asked about their satisfaction with the procedure. Results: Included in the final analysis were 19 patients (16 male, 3 female) with a mean age at surgery of 37.1 ± 12.6 years and a mean follow-up of 12.4 ± 1.5 years (range, 10-14 years). Five failures (26%) were reported: 1 CMI removal because of implant breakage and 4 joint replacements (2 unicompartmental knee arthroplasties and 2 total knee arthroplasties). The implant survival rate was 96% at 2 years, 85% at 5 years, 85% at 10 years, 77% at 12 years, and 64% at 14 years. Lysholm scores at the final follow-up were rated as “excellent” in 36% (5 of 14 nonfailures), “good” in 43% (6 of 14), and “fair” in 21% (3 of 14). The VAS score was 3.1 ± 3.1, with only 16% (3 of 19 patients) reporting that they were pain-free; the median Tegner score was 3 (interquartile range, 2-5). All clinical scores decreased from the 2-year follow-up; however, with the exception of the Tegner score, they remained significantly higher compared with the preoperative status. Overall, 79% of patients were willing to undergo the same procedure. Conclusion: Lateral CMI implantation for partial lateral meniscal defects provided good long-term results, with a 10-year survival rate of 85% and a 14-year survival rate of 64%. At the final follow-up, 58% of the patients had “good” or “excellent” Lysholm scores. However, there was a general decrease in outcome scores between the short- and the long-term follow-up.

Download Full-text

Long-term acrylamide exposure exacerbates brain and lung pathology in a mouse malaria model

Food and Chemical Toxicology ◽

10.1016/j.fct.2021.112132 ◽

2021 ◽

pp. 112132

Author(s):

Ha Ngo-Thanh ◽

Trang Dam Thuy ◽

Kazutomo Suzue ◽

Wataru Kamitani ◽

Hideaki Yokoo ◽

...

Keyword(s):

Lung Pathology ◽

Malaria Model

Download Full-text

Long-term subjective memory after electroconvulsive therapy

BJPsych Open ◽

10.1192/bjo.2020.9 ◽

2020 ◽

Vol 6 (2) ◽

Cited By ~ 6

Author(s):

Robert Sigström ◽

Axel Nordenskjöld ◽

Anders Juréus ◽

Caitlin Clements ◽

Erik Joas ◽

...

Keyword(s):

Electroconvulsive Therapy ◽

Memory Impairment ◽

Rating Scale ◽

Final Analysis ◽

Negative Effects ◽

Subjective Memory ◽

Subjective Memory Impairment ◽

Negative Effect ◽

Negative Expectations

Background There have been reports of long-term subjective memory worsening after electroconvulsive therapy (ECT). Aims To study the prevalence and risk factors of long-term subjective memory worsening among patients receiving ECT in routine clinical practice. Method Patients (n = 535, of whom 277 were included in the final analysis) were recruited from eight Swedish hospitals. Participants' subjective memory impairment was assessed before ECT and a median of 73 days after ECT using the memory item from the Comprehensive Psychopathological Rating Scale. Participants also rated their pre-ECT expectations and post-ECT evaluations of the effect of ECT on memory on a 7-point scale. We used ordinal regression to identify variables associated with subjective memory worsening and negative evaluations of the effect of ECT on memory. Results Comparisons of pre- and post-ECT assessments showed that subjective memory worsened in 16.2% of participants, remained unchanged in 52.3% and improved in 31.4%. By contrast, when asked to evaluate the effect of ECT on memory after treatment 54.6% reported a negative effect. Subjective memory worsening was associated with negative expectations before ECT, younger age and shorter duration of follow-up. Conclusions Although subjective memory improved more often than it worsened when assessed before and after ECT, a majority of patients reported that ECT had negative effects on their memory when retrospectively asked how ECT had affected it. This might suggest that some patients attribute pre-existing subjective memory impairment to ECT. Clinicians should be aware that negative expectations are associated with subjective worsening of memory after ECT.

Download Full-text

Hypocalcemic cardiomyopathy after parathyroidectomy in a patient with uremia: A case report and literature review

Journal of International Medical Research ◽

10.1177/0300060520942115 ◽

2020 ◽

Vol 48 (7) ◽

pp. 030006052094211

Author(s):

Wei Zhang ◽

Feng Xue ◽

Quandong Bu ◽

Xuemei Liu

Keyword(s):

Heart Failure ◽

Case Report ◽

Secondary Hyperparathyroidism ◽

Calcium Supplementation ◽

Severe Heart Failure ◽

Cardiac Complications ◽

Refractory Heart Failure ◽

First Case ◽

Insight Into

Hypocalcemia is a rare, but reversible, cause of dilated cardiomyopathy. Although cardiomyopathy may cause severe heart failure, calcium supplementation can reverse heart failure. We report here a patient with uremia and secondary hyperparathyroidism, who was complicated by persistent hypocalcemia and refractory heart failure. The cardiac failure was refractory to treatment with digitalis and diuretics, but dramatically responded to calcium therapy and restoration of normocalcemia. As a result, the patient was eventually diagnosed with hypocalcemic cardiomyopathy. To the best of our knowledge, this is the first case of this disease to be reported in a patient with uremia. Findings from our case may help clinicians to better understand hypocalcemic cardiomyopathy. Our case might also provide new insight into long-term cardiac complications and prognoses of patients undergoing parathyroidectomy due to secondary hyperparathyroidism.

Download Full-text

Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study

European Journal of Cancer ◽

10.1016/j.ejca.2020.12.022 ◽

2021 ◽

Vol 146 ◽

pp. 107-114

Author(s):

Giovanni Martinelli ◽

Nicolas Boissel ◽

Patrice Chevallier ◽

Oliver Ottmann ◽

Nicola Gökbuget ◽

...

Keyword(s):

Acute Lymphoblastic Leukaemia ◽

B Cell ◽

Lymphoblastic Leukaemia ◽

Philadelphia Chromosome ◽

Final Analysis ◽

Cell Precursor ◽

Long Term Follow Up ◽

Philadelphia Chromosome Positive

Download Full-text

MINIMAL LUNG PATHOLOGY IN LONG-TERM PRIMATE SURVIVORS OF HEART-LUNG TRANSPLANTATIO

Transplantation Journal ◽

10.1097/00007890-198712000-00030 ◽

1987 ◽

Vol 44 (6) ◽

pp. 852-854 ◽

Cited By ~ 3

Author(s):

Ari Harjula ◽

John C. Baldwin ◽

Henry D. Tazelaar ◽

Bruce A. Reitz ◽

Norman E. Shumway

Keyword(s):

Lung Pathology

Download Full-text

Long-term outcomes after prophylactic bursectomy in patients with resectable gastric cancer: Final analysis of a multicenter randomized controlled trial

Surgery ◽

10.1016/j.surg.2014.12.024 ◽

2015 ◽

Vol 157 (6) ◽

pp. 1099-1105 ◽

Cited By ~ 14

Author(s):

Motohiro Hirao ◽

Yukinori Kurokawa ◽

Junya Fujita ◽

Hiroshi Imamura ◽

Yoshiyuki Fujiwara ◽

...

Keyword(s):

Gastric Cancer ◽

Randomized Controlled Trial ◽

Controlled Trial ◽

Final Analysis ◽

Long Term Outcomes ◽

Randomized Controlled ◽

Multicenter Randomized Controlled Trial ◽

Resectable Gastric Cancer

Download Full-text

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years

Blood ◽

10.1182/blood-2016-09-742411 ◽

2017 ◽

Vol 129 (4) ◽

pp. 456-459 ◽

Cited By ~ 33

Author(s):

Maria Gavriatopoulou ◽

Ramón García-Sanz ◽

Efstathios Kastritis ◽

Pierre Morel ◽

Marie-Christine Kyrtsonis ◽

...

Keyword(s):

Stem Cell ◽

High Probability ◽

Final Analysis ◽

Phase 2 ◽

Newly Diagnosed ◽

Phase 2 Study ◽

Key Points ◽

Probability Of Response

Key Points BDR is a chemotherapy-free, non-stem-cell–toxic regimen associated with high response rates and long-term remissions. The long-term safety profile of BDR is favorable, with high probability of response to reintroduction of rituximab-based regimens at relapse.

Download Full-text